Evidence map›Paper›PMID 36786013›Full record

ArticleACS infectious diseases2023

In Vitro and In Vivo Development of a β-Lactam-Metallo-β-Lactamase Inhibitor: Targeting Carbapenem-Resistant

Byron K Peters, Nakita Reddy, Mbongeni Shungube, Letisha Girdhari, Sooraj Baijnath, Sipho Mdanda, Lloyd Chetty, Thandokuhle Ntombela, Thilona Arumugam, Linda A Bester and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Development andRSC advances · 2025
    Article
  5. Article
  6. Approachable Synthetic Methodologies for Second-GenerationPharmaceuticals (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Byron K PetersCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.ORCID 0000-0003-2889-1354
Nakita ReddyCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Mbongeni ShungubeCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Letisha GirdhariCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Sooraj BaijnathCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Sipho MdandaCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Lloyd ChettyCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Thandokuhle NtombelaCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Thilona ArumugamSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa.
Linda A BesterBiomedical Research Unit, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.
Sanil D SinghDepartment of Pharmaceutical Science, University of KwaZulu-Natal, Westville Campus, Durban 3629, South Africa.
Anil ChuturgoonSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa.ORCID 0000-0003-4649-4133
Per I ArvidssonCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Glenn E M MaguireCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.
Hendrik G KrugerCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.ORCID 0000-0003-0606-2053
Tricia NaickerCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban 4001, South Africa.ORCID 0000-0002-7134-6258
Thavendran GovenderDepartment of Chemistry, University of Zululand, Private Bag X1001, KwaDlangezwa, Empangeni 3886, South Africa.ORCID 0000-0003-2511-2503
University of KwaZulu-Natal · ZAScience for Life Laboratory · SEUniversity of the Witwatersrand · ZAUniversity of Zululand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-lactams are the most prescribed class of antibiotics due to their potent, broad-spectrum antimicrobial activities. However, alarming rates of antimicrobial resistance now threaten the clinical relevance of these drugs, especially for the carbapenem-resistant

Indexed as

beta-Lactamase InhibitorsCarbapenemsAnimalsAnti-Bacterial Agentsbeta-LactamsHumansLactamsMeropenemMiceMicrobial Sensitivity TestsMolecular Docking SimulationMonobactamsZincAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamsCarbapenemsLactamsMeropenemMonobactamsZinccarbapenem-resistant Enterobacteraleshuman hepatocarcinoma cellsKlebsiella pneumoniaeNew Delhi metallo β-lactamaseVerona integron-encoded MBLβ-Lactam-Metallo-β-Lactamase Inhibitor

Identifiers

PMID36786013
PMCPMC10012271
OpenAlexW4320710145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.